Your browser doesn't support javascript.
loading
Clinician Perspectives on Current Issues in Lung Cancer Drug Development.
Waqar, Saiama N; Bonomi, Philip D; Govindan, Ramaswamy; Hirsch, Fred R; Riely, Gregory J; Papadimitrakopoulou, Vassiliki; Kazandjian, Dickran; Khozin, Sean; Larkins, Erin; Dickson, Dane J; Malik, Shakun; Horn, Leora; Ferris, Andrea; Shaw, Alice T; Jänne, Pasi A; Mok, Tony S K; Herbst, Roy; Keegan, Patricia; Pazdur, Richard; Blumenthal, Gideon M.
Afiliación
  • Waqar SN; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Bonomi PD; Rush University Medical Center, Chicago, Illinois.
  • Govindan R; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Hirsch FR; University of Colorado Cancer Center, Denver, Colorado.
  • Riely GJ; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Papadimitrakopoulou V; The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
  • Kazandjian D; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Khozin S; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Larkins E; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Dickson DJ; Oregon Health and Science University, Portland, Oregon.
  • Malik S; National Cancer Institute, Bethesda, Maryland.
  • Horn L; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Ferris A; LUNGevity Foundation, Bethesda, Maryland.
  • Shaw AT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Jänne PA; Dana Farber Cancer Institute, Boston, Massachusetts.
  • Mok TS; The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Herbst R; Yale School of Medicine, New Haven, Connecticut.
  • Keegan P; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Pazdur R; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Blumenthal GM; U.S. Food and Drug Administration, Silver Spring, Maryland. Electronic address: Gideon.Blumenthal@fda.hhs.gov.
J Thorac Oncol ; 11(9): 1387-96, 2016 09.
Article en En | MEDLINE | ID: mdl-27401214
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2016 Tipo del documento: Article